Newamsterdam Pharma Company N.V. (NAMS) Stock Price, Quote & News

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewA...

Industry: Biotechnology

Sector: Healthcare

Phone: 31 35 206 2971

Website: www.newamsterdampharma.com

Address:

Gooimeer 2-35, Naarden, Netherlands

GeologistG Dec. 25 at 11:23 AM

$NAMS The next leg of valuation movement will likely hinge on how management navigates competing priorities. Resource allocation will signal whether leadership prioritizes endurance or speed. Successful iteration can create optionality that is not yet fully priced. Investors will likely wait for pattern recognition before re‑committing capital.

0 · Reply

Petey3163 Dec. 19 at 10:55 PM

$ESPR we have amazing news and $NAMS has a better day? 😂

1 · Reply

newfguy Dec. 19 at 5:58 PM

$NAMS buy all weakness

0 · Reply

Albertowest Dec. 18 at 11:03 AM

$NAMS beware of the final rug pull

0 · Reply

JarvisFlow Dec. 16 at 5:29 PM

Stifel has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 44 → 50.

0 · Reply

LuckyGuy9 Dec. 12 at 11:09 PM

$NAMS Brand new here and I’m very interested in learning more about this company. Any resident bulls I need to read up on? I wanna know what’s a good entry, future catalysts, and what’s a reasonable timeline for an exit. Also what are the possible downsides the community might be concerned with

1 · Reply

newfguy Dec. 10 at 6:25 PM

$NAMS MAA submission to EMA was August 18, expected approval for EU market July to September 2026

0 · Reply

BillionerOfKing Dec. 9 at 11:07 PM

$NAMS Current Stock Price: $34.80 Contracts to trade: $35 NAMS Dec 19 2025 Call Entry: $0.20 Exit: $0.36 ROI: 82% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

CaptainAmrica Dec. 9 at 2:33 PM

$NAMS... Its been a good trade.

1 · Reply

CH_Expat Dec. 8 at 9:51 PM

$NAMS Interested here. Bit lower would be better.

1 · Reply

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 3, 2025, 6:33 PM EST - 5 weeks ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Nov 25, 2025, 8:00 AM EST - 6 weeks ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

Nov 16, 2025, 10:30 AM EST - 7 weeks ago

NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating

Nov 5, 2025, 8:00 AM EST - 2 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

Oct 30, 2025, 8:00 AM EDT - 2 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in November

Sep 24, 2025, 8:00 AM EDT - 3 months ago

NewAmsterdam Pharma to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Sep 3, 2025, 10:22 PM EDT - 4 months ago

NewAmsterdam Pharma Company N.V. (NAMS) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 8:00 AM EDT - 4 months ago

NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Aug 21, 2025, 2:41 AM EDT - 4 months ago

Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site

Aug 18, 2025, 8:00 AM EDT - 5 months ago

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

Aug 6, 2025, 7:00 AM EDT - 5 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

Jul 30, 2025, 8:25 AM EDT - 5 months ago

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer's Disease Biomarkers at AAIC 2025

Jul 22, 2025, 8:00 AM EDT - 6 months ago

NewAmsterdam Pharma to Present Alzheimer's Biomarker Data from BROADWAY Trial at AAIC 2025

Jun 9, 2025, 7:00 AM EDT - 7 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer's Disease Data from BROADWAY Clinical Trial

Jun 5, 2025, 8:00 AM EDT - 7 months ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

May 27, 2025, 8:00 AM EDT - 8 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

May 14, 2025, 8:00 AM EDT - 8 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

May 8, 2025, 8:00 AM EDT - 8 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

May 7, 2025, 7:15 AM EDT - 8 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

Apr 30, 2025, 8:00 AM EDT - 9 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

Mar 31, 2025, 8:00 AM EDT - 10 months ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

Feb 28, 2025, 11:26 PM EST - 11 months ago

NewAmsterdam Pharma: Significant Upside Possible In Case Of Approval Of Obicetrapib

Feb 28, 2025, 10:48 AM EST - 11 months ago

NewAmsterdam Pharma: A Mispriced Bet On A Cholesterol Revolution

Feb 26, 2025, 8:00 AM EST - 11 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

Feb 25, 2025, 8:00 AM EST - 11 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Dec 13, 2024, 5:16 PM EST - 1 year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 11, 2024, 9:37 PM EST - 1 year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 11, 2024, 1:33 PM EST - 1 year ago

NewAmsterdam Pharma: Positive Obicetrapib Data Leads To New Catalysts

Dec 11, 2024, 6:55 AM EST - 1 year ago

Top 3 Health Care Stocks That May Collapse This Quarter

ADPT FNA

Dec 10, 2024, 4:34 PM EST - 1 year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Dec 10, 2024, 11:14 AM EST - 1 year ago

Why Is NewAmsterdam Pharma Stock Trading Higher On Tuesday?

Dec 10, 2024, 7:00 AM EST - 1 year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

Nov 18, 2024, 3:20 PM EST - 1 year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

Oct 28, 2024, 4:30 PM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Oct 4, 2024, 12:09 PM EDT - 1 year ago

Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies

Aug 30, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

Aug 28, 2024, 1:33 PM EDT - 1 year ago

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside

Jul 26, 2024, 4:01 PM EDT - 1 year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

Jul 8, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

Jul 5, 2024, 1:40 PM EDT - 1 year ago

NewAmsterdam Pharma: Cholesterol Drug Treatment With Catalysts In 1-Year Period

Apr 9, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

Apr 9, 2024, 8:00 AM EDT - 1 year ago

BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors

Apr 1, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

Mar 25, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Mar 12, 2024, 8:00 AM EDT - 1 year ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

Feb 28, 2024, 8:00 AM EST - 2 years ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Feb 13, 2024, 10:40 PM EST - 2 years ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 13, 2024, 4:01 PM EST - 2 years ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Feb 1, 2024, 4:01 PM EST - 2 years ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GeologistG Dec. 25 at 11:23 AM

0 · Reply

Petey3163 Dec. 19 at 10:55 PM

$ESPR we have amazing news and $NAMS has a better day? 😂

1 · Reply

newfguy Dec. 19 at 5:58 PM

$NAMS buy all weakness

0 · Reply

Albertowest Dec. 18 at 11:03 AM

$NAMS beware of the final rug pull

0 · Reply

JarvisFlow Dec. 16 at 5:29 PM

Stifel has adjusted their stance on NewAmsterdam Pharma Co ( $NAMS ), setting the rating to Buy with a target price of 44 → 50.

0 · Reply

LuckyGuy9 Dec. 12 at 11:09 PM

1 · Reply

newfguy Dec. 10 at 6:25 PM

$NAMS MAA submission to EMA was August 18, expected approval for EU market July to September 2026

0 · Reply

BillionerOfKing Dec. 9 at 11:07 PM

0 · Reply

CaptainAmrica Dec. 9 at 2:33 PM

$NAMS... Its been a good trade.

1 · Reply

CH_Expat Dec. 8 at 9:51 PM

$NAMS Interested here. Bit lower would be better.

1 · Reply

masonat Dec. 4 at 1:36 PM

$NAMS Piper analyst today was straight up fangirling over CEO Michael Davidson on the call 🤣 Yesterday's call was more worth a listen imo.

1 · Reply

newfguy Dec. 3 at 8:58 PM

$NAMS another strong presentation by CEO and CFO

2 · Reply

McLarkin Dec. 3 at 8:53 PM

$NAMS lots exciting things coming here through 2026... sitting on my hands and holding since early this year.....

0 · Reply

newfguy Dec. 3 at 8:43 PM

$NAMS sellers aren't listening to nor understanding NAMS investor conference presentations

0 · Reply

Finlay2 Dec. 3 at 8:36 PM

$NAMS was something new said at today’s conference?

2 · Reply

tttggg Dec. 3 at 8:25 PM

$NAMS what’s going on here? Emmm

0 · Reply

newfguy Dec. 3 at 6:09 PM

$NAMS yet another BTFD day

0 · Reply

newfguy Dec. 3 at 5:06 PM

$NAMS CFO expects more commercial success for obi than Merck oral PCSK9 drug. Merck expects to achieve $5B/year sales for new drug.

0 · Reply

masonat Dec. 2 at 9:28 PM

$NAMS Sounds like alzheimer's phase 2b will include secondary cognitive endpoints. Happy to see that but also hope people don't discouraged if there is no strong cognitive signal in what will probably be a pretty short trial (1-2 years). Also hoping they test on patients without cognitive impairment.

0 · Reply

newfguy Dec. 2 at 8:58 PM

$NAMS https://wsw.com/webcast/evercore52/nams/2364670

0 · Reply

erevnon Dec. 2 at 7:00 PM

Goldman Sachs maintains NewAmsterdam Pharma Co $NAMS at Neutral and raises the price target from $30 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

JarvisFlow Dec. 2 at 6:16 PM

Goldman Sachs has updated their rating for NewAmsterdam Pharma Co ( $NAMS ) to Neutral with a price target of 37.

0 · Reply

Market Cap	3.99B
Revenue (ttm)	45.56M
Net Income (ttm)	-241.60M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-530.29%
Debt to Equity Ratio	0.00

Volume	759,782
Avg Vol	969,650
Day's Range	N/A - N/A
Shares Out	113.39M
Stochastic %K	32%
Beta	0.07
Analysts	Strong Sell
Price Target	$47.42